(Reuters) -The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' drug to treat acute pain, the health ...
Shares of Vertex Pharmaceuticals rose after Journavx, the company’s oral non-opioid pain medication, received Food and Drug ...
The Vertex drug is a milestone after a long history of unsuccessful efforts to develop painkillers without the addictive ...
Vertex Pharmaceuticals won FDA approval for its non-opioid painkiller Journavx. Vertex stock jumped in late trading.
The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals’ Journavx for short-term pain that often ...
Vertex Pharmaceuticals on Thursday won approval from the Food and Drug Administration for a non-opioid pain drug, clearing ...
Vertex Pharmaceuticals Inc. (VRTX) has secured FDA approval for Suzetrigine, an oral, non-opioid, highly selective NaV1.8 pain signal ...
The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVXâ„¢ (suzetrigin ...
Despite high demand for an option like Journavx, doctors fear the drug’s price could be a major hangup for insurers, potentially limiting patients’ ability to access it.
Federal officials on Thursday approved a new type of pain pill designed to eliminate the risks of addiction and overdose ...
The FDA approved Vertex Pharmaceuticals’ Journavx, a new non-opioid pain pill for short-term pain. While safer than opioids, ...